Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study

Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study

Show other versions (1)

Introduction and aims: To determine the prevalence of minimal hepatic encephalopathy (MHE) in patients with liver cirrhosis (LC) due to hepatitis C virus (HCV) infection and to evaluate the impact of sustained viral response (SVR) on MHE. Material and methods: We performed a prospective study using...

Full description

Bibliographic Details
Main Authors:	Marta Hernández-Conde, Carlos Fernández-Carrillo, Elba Llop, Christie Perelló, Marta López-Gómez, José L. Martínez-Porras, Natalia Fernández-Puga, José L. Calleja
Format:	Article
Language:	English
Published:	Elsevier 2019-01-01
Series:	Annals of Hepatology
Subjects:	HCV MHE Direct-acting antivirals Critical flicker frequency
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268119303230

Similar Items

Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study
by: Marta Hernández-Conde, et al.
Published: (2019-05-01)

Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction
by: Praveen Sharma, et al.
Published: (2012-01-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022-02-01)

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
by: Soraya Abad, et al.
Published: (2017-03-01)

HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
by: Curtis L. Cooper, et al.
Published: (2019-08-01)

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
by: Polilli E, et al.
Published: (2016-09-01)

Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection
by: El-Araby Mohamed Ibrahim Shalaby, et al.
Published: (2023-06-01)

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States
by: Haesuk Park, et al.
Published: (2023-04-01)

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office
by: Karem Aline Pegoraro, et al.
Published: (2023-11-01)

SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient
by: Sara Lo Menzo, et al.
Published: (2018-07-01)

THE APPLICATION OF CRITIC-TOPSIS METHOD IN SOLVING THE MATERIAL HANDLING EQUIPMENT SELECTION PROBLEM
by: Nurul Anis Yazid, et al.
Published: (2023-04-01)

Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy
by: Roberto Ravasio, et al.
Published: (2020-12-01)

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
by: von Massow G, et al.
Published: (2019-04-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
by: Hassan AM, et al.
Published: (2018-06-01)

Virologic Tools for HCV Drug Resistance Testing
by: Slim Fourati, et al.
Published: (2015-12-01)

Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection
by: Ahmad M. Zidan, et al.
Published: (2021-05-01)

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients
by: Asmaa M. Elbrolosy, et al.
Published: (2021-03-01)

Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience
by: José A. del Campo, et al.
Published: (2018-02-01)

A clinical case of three times treatment of hepatitis C with repeated infection in HIV-positive patient. Case Report
by: Anastasia V. Pokrovskaya, et al.
Published: (2023-12-01)

Usefulness of Sofosbuvir and Daclatasvir combination in the treatment of HCV infection in childhood cancer patients: experience from a tertiary care hospital
by: Uzma Imam, et al.
Published: (2023-10-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome
by: Sabrina Bagaglio, et al.
Published: (2020-02-01)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
by: Luca Rinaldi, et al.
Published: (2019-08-01)

Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients
by: Crina Fofiu, et al.
Published: (2019-01-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease
by: Agatha Vranjkovic, et al.
Published: (2019-08-01)

Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy
by: Laura Tarancon-Diez, et al.
Published: (2023-06-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Chronic HCV infection: An internist’s opinion (Part 2)
by: M L Zubkin, et al.
Published: (2016-11-01)

Critical flicker frequency: A useful tool in diagnosis of minimal hepatic encephalopathy
by: Sukanya Bhrugumalla, et al.
Published: (2018-01-01)

Screening for minimal hepatic encephalopathy among asymptomatic drivers with chronic liver disease
by: Mohammad Eltaher Abdelrahman, et al.
Published: (2018-01-01)

Berthing Trajectory Tracking of Underactuated Surface Vehicle Based on NMPC and Position Estimation
by: Zuxin Wu, et al.
Published: (2024-01-01)

Rapidly acquired valgus deformity of the knee after osteochondroma resection in multiple hereditary exostoses pediatric patients: A report of two cases
by: Alexandra H. Aitchison, BS, et al.
Published: (2022-01-01)

A Comparative Study on the Presence and Reversibility of Subclinical Arterial Damage in HCV-Infected Individuals and Matched Controls
by: Theodoros Androutsakos, et al.
Published: (2023-06-01)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
by: Hafiza Arooba Riaz, et al.
Published: (2023-05-01)

Serum retinol-binding protein 4 as a predictor of fibrosis regression and response to direct-acting antiviral drugs in chronic hepatitis C virus patients
by: Hany Samir Rasmy, et al.
Published: (2023-03-01)

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report
by: Michiko Shimada, et al.
Published: (2017-03-01)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review
by: Giacomo Gastaldi, et al.
Published: (2017-03-01)